List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6950012/publications.pdf Version: 2024-02-01



Ιοςà Ο Μ Ι ΔΝΑΟ

#	Article	IF	CITATIONS
1	Critical factors in the release of drugs from sustained release hydrophilic matrices. Journal of Controlled Release, 2011, 154, 2-19.	9.9	405
2	Current applications of nanoparticles in infectious diseases. Journal of Controlled Release, 2016, 224, 86-102.	9.9	321
3	Delivery systems to increase the selectivity of antibiotics in phagocytic cells. Journal of Controlled Release, 2008, 125, 210-227.	9.9	187
4	Drug, enzyme and peptide delivery using erythrocytes as carriers. Journal of Controlled Release, 2004, 95, 27-49.	9.9	165
5	Targeting of Hepatic Macrophages by Therapeutic Nanoparticles. Frontiers in Immunology, 2020, 11, 218.	4.8	94
6	Enteric coating of oral solid dosage forms as a tool to improve drug bioavailability. European Journal of Pharmaceutical Sciences, 2019, 138, 105019.	4.0	78
7	Recent advances in colon drug delivery systems. Journal of Controlled Release, 2020, 327, 703-724.	9.9	78
8	Population pharmacokinetics of amikacin in patients with haematological malignancies. Journal of Antimicrobial Chemotherapy, 1999, 44, 235-242.	3.0	70
9	High-performance liquid chromatographic validated assay of doxorubicin in rat plasma and tissues. Biomedical Applications, 1999, 721, 271-278.	1.7	59
10	Factors associated with the performance of carrier erythrocytes obtained by hypotonic dialysis. Blood Cells, Molecules, and Diseases, 2004, 33, 132-140.	1.4	58
11	Drug-loaded erythrocytes: on the road toward marketing approval. Drug Design, Development and Therapy, 2016, 10, 665.	4.3	57
12	Population pharmacokinetics of caffeine in premature neonates. European Journal of Clinical Pharmacology, 1997, 52, 211-217.	1.9	52
13	Cell-based drug-delivery platforms. Therapeutic Delivery, 2012, 3, 25-41.	2.2	52
14	Advances in Exosomesâ€Based Drug Delivery Systems. Macromolecular Bioscience, 2021, 21, e2000269.	4.1	51
15	Recent advances in functionalized nanomaterials for the diagnosis and treatment of bacterial infections. Materials Science and Engineering C, 2021, 121, 111843.	7.3	47
16	Pharmacokinetic basis for the use of extended interval dosage regimens of gentamicin in neonates. Journal of Antimicrobial Chemotherapy, 2004, 54, 193-198.	3.0	46
17	Nanoparticles for Signaling in Biodiagnosis and Treatment of Infectious Diseases. International Journal of Molecular Sciences, 2018, 19, 1627.	4.1	44
18	Population Pharmacokinetics of Gentamicin in Premature Infants. Therapeutic Drug Monitoring, 1992, 14, 177-183.	2.0	38

#	Article	IF	CITATIONS
19	Drug Tissue Distribution: Study Methods and Therapeutic Implications. Current Pharmaceutical Design, 2005, 11, 3829-3845.	1.9	37
20	Recent advances in delivery systems for anti-HIV1 therapy. Journal of Drug Targeting, 2007, 15, 21-36.	4.4	37
21	Influence of Clinical Diagnosis in the Population Pharmacokinetics of Amikacin in Intensive Care Unit Patients. Clinical Drug Investigation, 1998, 15, 435-444.	2.2	29
22	PHARMACOKINETICS OF RECTAL KETAMINE IN CHILDREN. British Journal of Anaesthesia, 1989, 63, 671-674.	3.4	28
23	Determination of netilmicin in plasma by HPLC. Journal of Pharmaceutical and Biomedical Analysis, 1995, 13, 1059-1062.	2.8	23
24	Bayesian Forecasting in Paediatric Populations. Clinical Pharmacokinetics, 1996, 31, 325-330.	3.5	23
25	In vitro studies of amikacin-loaded human carrier erythrocytes. Translational Research, 2008, 152, 59-66.	5.0	23
26	Kinetics of ketamine and its metabolites in rabbits with normal and impaired renal function. European Journal of Drug Metabolism and Pharmacokinetics, 1985, 10, 33-39.	1.6	21
27	Pharmacokinetics of amikacin in intensive care unit patients. Journal of Clinical Pharmacy and Therapeutics, 1996, 21, 417-421.	1.5	20
28	Encapsulation andIn VitroEvaluation of Amikacin-Loaded Erythrocytes. Drug Delivery, 2005, 12, 409-416.	5.7	20
29	Gold Nanocarriers for Macrophageâ€Targeted Therapy of Human Immunodeficiency Virus. Macromolecular Bioscience, 2017, 17, 1600359.	4.1	20
30	Time-dependent pharmacokinetics of cyclosporine (NeoralR) in de novo renal transplant patients. Journal of Clinical Pharmacy and Therapeutics, 2005, 30, 549-557.	1.5	18
31	Pharmacokinetics and biodistribution of amikacin encapsulated in carrier erythrocytes. Journal of Antimicrobial Chemotherapy, 2007, 61, 375-381.	3.0	18
32	Study of the factors influencing the encapsulation of zidovudine in rat erythrocytes. International Journal of Pharmaceutics, 2010, 401, 41-46.	5.2	17
33	High performance liquid chromatography determination of doxorubicin and daunorubicin in plasma using UV detection and column switching. Biomedical Chromatography, 1990, 4, 154-156.	1.7	16
34	Bioavailability of rectally administered naproxen. International Journal of Pharmaceutics, 1987, 38, 117-122.	5.2	15
35	Evaluating amikacin dosage regimens in intensive care unit patients: A pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation. International Journal of Antimicrobial Agents, 2013, 42, 155-160.	2.5	15
36	Pharmacokinetics and dosing requirements of digoxin in pregnant women treated for fetal supraventricular tachycardia. Expert Review of Clinical Pharmacology, 2017, 10, 911-917.	3.1	15

#	Article	IF	CITATIONS
37	Increasing the selectivity of amikacin in rat peritoneal macrophages using carrier erythrocytes. European Journal of Pharmaceutical Sciences, 2009, 38, 320-324.	4.0	14
38	Therapeutic Monitoring of Warfarin: the Appropriate Response Marker. Journal of Pharmacy and Pharmacology, 2010, 52, 1405-1410.	2.4	14
39	Effect of renal impairment on distribution of ofloxacin. Antimicrobial Agents and Chemotherapy, 1990, 34, 455-459.	3.2	13
40	Evaluation of Thermodynamic Lonization Constants by Computation of Spectrophotometric and Potentiometric Experimental Data Obtained Simultaneously from a Flow System. Journal of Pharmaceutical Sciences, 1992, 81, 592-596.	3.3	13
41	A comparative study of ofloxacin and ciprofloxacin erythrocyte distribution. , 1998, 19, 71-77.		12
42	New erythrocyte-related delivery systems for biomedical applications. Journal of Drug Delivery Science and Technology, 2017, 42, 38-48.	3.0	12
43	DETERMINATION OF AMBROXOL HYDROCHLORIDE BY HPLC. Journal of Liquid Chromatography and Related Technologies, 2001, 24, 1007-1014.	1.0	11
44	Population pharmacokinetics of high dose ibuprofen in cystic fibrosis. Archives of Disease in Childhood, 2003, 88, 1128-1130.	1.9	11
45	Pharmacokinetics of cephacetrile in patients undergoing haemodialysis. European Journal of Clinical Pharmacology, 1979, 16, 49-52.	1.9	10
46	Distribution of ciprofloxacin in the isolated rat lung in the presence and absence of tissue oedema. European Journal of Pharmaceutical Sciences, 1999, 8, 203-209.	4.0	10
47	Approaches for dosage individualisation in critically ill patients. Expert Opinion on Drug Metabolism and Toxicology, 2013, 9, 1481-1493.	3.3	10
48	Thyroxine and Triiodothyronine Kinetics and Extrathyroidal Peripheral Conversion Rate of Thyroxine to Triiodothyronine in Healthy Elderly Humans. Hormone and Metabolic Research, 1981, 13, 626-631.	1.5	9
49	Pharmacokinetics of cefazolin administered as a new drug delivery system in healthy volunteers. Biopharmaceutics and Drug Disposition, 1988, 9, 377-388.	1.9	9
50	Modification in the pharmacokinetics of amikacin during development. European Journal of Clinical Pharmacology, 1982, 23, 155-160.	1.9	8
51	Amikacin concentrations in serum and blister fluid in healthy volunteers and in patients with renal impairment. Journal of Antimicrobial Chemotherapy, 1983, 12, 481-488.	3.0	8
52	Serum Lidocaine Levels in Patients Undergoing Fibrobronchoscopy. Therapeutic Drug Monitoring, 1983, 5, 201-204.	2.0	8
53	Influence of flow rate on the disposition of levofloxacin and netilmicin in the isolated rat lung. European Journal of Pharmaceutical Sciences, 2005, 24, 325-332.	4.0	8

54 Applications of Metallic Nanoparticles in Antimicrobial Therapy. , 2017, , 411-444.

8

JOSé M LANAO

#	Article	IF	CITATIONS
55	Influence of Pharmacokinetic Model on Vancomycin Peak Concentration Targets. Therapeutic Drug Monitoring, 1996, 18, 145-148.	2.0	8
56	A review of the isolated kidney as an experimental model for pharmacokinetic studies. Methods and Findings in Experimental and Clinical Pharmacology, 2000, 22, 757.	0.8	8
57	Cell-Based Drug Delivery Platforms. Pharmaceutics, 2021, 13, 2.	4.5	8
58	Influence of the route of administration on the pharmacokinetics of amikacin. European Journal of Clinical Pharmacology, 1981, 19, 367-370.	1.9	7
59	Pharmacokinetic and nephrotoxic study of gentamicin in rabbits using a new dosage regimen. European Journal of Drug Metabolism and Pharmacokinetics, 1989, 14, 169-175.	1.6	7
60	POPULATION PHARMACOKINETIC STUDY OF GENTAMICIN AND A BAYESIAN APPROACH IN PATIENTS WITH RENAL IMPAIRMENT. Journal of Clinical Pharmacy and Therapeutics, 1989, 14, 213-223.	1.5	7
61	Digoxin pharmacokinetics in patients with high serum digoxin concentrations. Journal of Clinical Pharmacy and Therapeutics, 1993, 18, 63-68.	1.5	7
62	Evaluation of renal function equations to predict amikacin clearance. Expert Review of Clinical Pharmacology, 2019, 12, 805-813.	3.1	7
63	Physiologically Based Pharmacokinetic (PBPK) Model of Gold Nanoparticle-Based Drug Delivery System for Stavudine Biodistribution. Pharmaceutics, 2022, 14, 406.	4.5	7
64	Disposition of dibekacin in patients undergoing haemodialysis. European Journal of Clinical Pharmacology, 1980, 18, 347-350.	1.9	6
65	Pharmacokinetics of amikacin in children with normal and impaired renal function. Kidney International, 1981, 20, 115-121.	5.2	6
66	DETERMINATION OF AMIKACIN IN BIOLOGICAL TISSUES BY HPLC. Journal of Liquid Chromatography and Related Technologies, 2002, 25, 463-473.	1.0	6
67	Comparative study of the disposition of levofloxacin, netilmicin and cefepime in the isolated rat lungâ€. Journal of Pharmacy and Pharmacology, 2010, 57, 861-867.	2.4	6
68	Optimization of Release Kinetics from Sustained-Release Formulations using Model-Independent Pharmacokinetic Simulation. Journal of Pharmaceutical Sciences, 2011, 100, 3260-3267.	3.3	6
69	Influence of diagnostic and treatment factors in the population pharmacokinetics of gentamicin. Journal of Clinical Pharmacy and Therapeutics, 1998, 23, 141-148.	1.5	6
70	Elimination of cefroxadine (CGP-9000) from patients undergoing dialysis. European Journal of Clinical Pharmacology, 1983, 24, 109-112.	1.9	5
71	The biotransformation kinetics of Ketamine"in vitro―in rabbit liver and lung microsome fractions. European Journal of Drug Metabolism and Pharmacokinetics, 1986, 11, 9-16.	1.6	5
72	Pharmacokinetics of dibekacin in young adult and geriatric patients. Journal of Antimicrobial Chemotherapy, 1980, 6, 737-742.	3.0	4

#	Article	IF	CITATIONS
73	Non-linear tissue binding of amikacin in rats: the effect of renal impairment. European Journal of Drug Metabolism and Pharmacokinetics, 1987, 12, 193-201.	1.6	4
74	Choice of optimum pharmacokinetic model of orally administered paracetamol. Biopharmaceutics and Drug Disposition, 1988, 9, 389-396.	1.9	4
75	A Computer Program(DCN) for Numerical Convolution and Deconvolution of Pharmacokinetic Functions Journal of Pharmacobio-dynamics, 1992, 15, 203-214.	0.5	4
76	Pharmacokinetic parameters of netilmicin and protective effect of piperacillin regarding nephrotoxicity caused by netilmicin. European Journal of Drug Metabolism and Pharmacokinetics, 1998, 23, 143-147.	1.6	4
77	DETERMINATION OF AMIKACIN IN BIOLOGICAL TISSUES BY HPLC. Journal of Liquid Chromatography and Related Technologies, 2002, 25, 287-297.	1.0	4
78	Amikacin initial dosage in patients with hypoalbuminaemia: an interactive tool based on a population pharmacokinetic approach. Journal of Antimicrobial Chemotherapy, 2020, 75, 2222-2231.	3.0	4
79	Evaluation of Current Amikacin Dosing Recommendations and Development of an Interactive Nomogram: The Role of Albumin. Pharmaceutics, 2021, 13, 264.	4.5	4
80	Cells and Cell Ghosts as Drug Carriers. , 2006, , 329-348.		4
81	Ceforanide pharmacokinetics in haemodialysis: The effect of ultrafiltration. Biopharmaceutics and Drug Disposition, 1986, 7, 335-346.	1.9	3
82	Distribution kinetics of netilmicin in human blister fluid: Effect of renal impairment. Biopharmaceutics and Drug Disposition, 1991, 12, 149-162.	1.9	3
83	A comparative study of the population pharmacokinetics of gentamicin and amikacin in newborn patients. Journal of Clinical Pharmacy and Therapeutics, 1993, 18, 411-413.	1.5	3
84	Influence of the infusion rate on disposition of netilmicin in the isolated rat perfused kidney. European Journal of Pharmaceutical Sciences, 2002, 16, 133-141.	4.0	3
85	Evaluation of population pharmacokinetic models for amikacin dosage individualization in critically ill patients. Journal of Pharmacy and Pharmacology, 2010, 61, 759-766.	2.4	3
86	Influence of dose on the disposition kinetics of netilmicin in the isolated kidney of the rat. European Journal of Drug Metabolism and Pharmacokinetics, 2002, 27, 127-133.	1.6	1
87	Influence of Verapamil and Digoxin on the in Vitro Binding of Doxorubicin to the Rat Heart Biological and Pharmaceutical Bulletin, 1998, 21, 839-843.	1.4	0
88	Clinical Pharmacokinetic Applications of Recirculatory Models. , 2015, , .		0
89	Virtual congresses for pharmaceutical learning. , 2013, , .		0
90	Nanoparticle Production for Biomedical Applications via Laser Ablation Synthesis in Solution. , 2013, , 283-308.		0